Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

Empliciti’s FDA approval was based on results from the ELOQUENT-2 Phase III clinical study. Image: courtesy of Bristol-Myers Squibb.



  • Empliciti
  • Empliciti
  • Empliciti
Close
Close
Close

Go Top